A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...
Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...
Canadian biotech Oncolytics Biotech (Nasdaq: ONCY) has reported encouraging clinical and translational data for its oncolytic ...
Garsorasib shrank tumours in nearly half of patients with KRAS G12C pancreatic cancer and showed manageable side effects.
Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to ...
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced ...
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing ...
Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies([1]) , with the FDA fast-tracking multiple targeted therapies designed to ...
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback